Search results for Chiesi Group

Chiesi Group Grows Again in Rare Disease With $1.9B KalVista Acquisition

KalVista Pharmaceuticals brings to Chiesi Group the product Ekterly, the first FDA-approved oral drug for acute treatment of swelling attacks from the rare disease hereditary angio...

Chiesi Group Announces New Chair and Vice Chair

Highlights: Planned transition in the Chair and Vice Chair roles reflects the Chiesi family’s long-term commitment to continuity, shared value and responsible governance across gen...

Chiesi to buy KalVista in $1.9B deal for rare disease drug

The acquisition is the fifth of a biotech company so far this week and, according to some Wall Street analysts, proves pharma’s interest in new and emerging oral therapies for here...

<![CDATA[GSK Enters Exclusive Collaboration with SBP Group to Accelerate Bepirovirsen at Launch in Mainland China ]]&...

<![CDATA[FDA Approves Bizengri for Adults with NRG1 Fusion-Positive Cholangiocarcinoma]]>

<![CDATA[Angelini Pharma Enters $ 4.1 Billion Agreement to Acquire Catalyst Pharmaceuticals ]]>

<![CDATA[Rigel Pharmaceuticals Enters $85 Million Agreement for Exclusive Global Rights to Veppanu]]>

<![CDATA[Haisco Enters $745 Million Exclusive License Agreement with AbbVie ]]>

<![CDATA[Boehringer Ingelheim Expands Immunology Pipeline With Preclinical Antibody Licensing Deal]]>

<![CDATA[Global leader in engagement with healthcare stakeholders]]>

<![CDATA[UCB Enters $2.2 Billion Agreement to Acquire Candid Therapeutics ]]>

<![CDATA[FDA Approves Fasenra for Hypereosinophilic Syndrome]]>

<![CDATA[Pharmaceutical Executive Daily: GSK Enters Collaboration to Support Launch of Bepirovirsen]]>

<![CDATA[Gilead Enters $5 Billion Agreement to Acquire Tubulis ]]>

Efzimfotase alfa demonstrated positive results from global Phase III clinical programme in hypophosphatasia

This announcement contains inside information CHESTNUT randomised, open-label, active-controlled trial demonstrated safety and tolerability of efzimfotase alfa in paediatric patie...

<![CDATA[Regeneron Enters $2.3 Billion Collaboration with Parabilis Medicines to Discover & Develop Multiple Ther...

<![CDATA[Pharmaceutical Executive Daily: FDA Approves Breztri]]>

Recordati Industria Chimica e Farmaceutica S.p.A. 2026 Q1 - Results - Earnings Call Presentation

<![CDATA[Pharma M&A Roundup: Bayer to Acquire Perfuse Therapeutics, Madrigal Enters Licensing Agreement for ARO-P...

<![CDATA[FDA Extends Priority Review of Leqembi Iqlik Subcutaneous Injection ]]>

<![CDATA[Asembia ASX26: Inizio Launches Next-Generation Hub Services ]]>

<![CDATA[Pharmaceutical Executive Daily: Angelini Pharma Acquires Catalyst Pharmaceuticals in $4.1 Billion Agreement]...

<![CDATA[Eli Lilly Enters $202 Million Agreement to Acquire Engage Bio]]>

JASCAYD® (nerandomilast) approved in Japan, advancing global access to a new IPF and PPF treatment

Not intended for UK and US audiences JASCAYD® (nerandomilast) now approved by Japan’s MHLW for the treatment of adults with idiopathic pulmonary fibrosis and adults with progressiv...